Still, many physicians give 4 cycles of combination therapy to multiple myeloma patients prior to collection of stem cells for autologous bone marrow transplant. This tradition originates from older doxorubicin-containing regiments which limited the number of cycles due to cumulative cardiotoxicity. Using older regiments, most patients had residual myeloma cells in their autologous stem-cell grafts during collection. Emerging data show that newly diagnosed multiple myeloma patients treated with modern carfilzomib/lenalidomide/dexamethasone (KRd) therapy, on average, take 6 cycles until reaching minimal residual disease (MRD) negativity. We assessed newly diagnosed patients treated with KRd focusing MRD status both in the individual patient's bone marrow, and the corresponding autologous hematopoietic progenitor cell grafts during collection. Per protocol, stem-cell collection was allowed after 4 to 8 cycles of KRd. We found similar stem-cell yield independent of the number of cycles of KRd. At stem-cell collection, 11/30 patients (36.6%) were MRD negative in their bone marrow; all 11 patients had MRD negative hematopoietic progenitor cell grafts. Furthermore, 18/19 patients who were MRD positive in their bone marrows also had MRD negative hematopoietic progenitor cell grafts. These observations support 6 cycles of KRd as an efficacious and safe induction strategy prior to stem-cell collection.
Based on available data, most multiple myeloma patients have residual myeloma cells in their autologous hematopoietic progenitor cells (HPC) grafts during collection for autologous stemcell transplant (ASCT) [1, 2] . However, available literature is based on older induction regimens, such as vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) or vincristine, adriamycin and dexamethasone (VAD) [1, 3] . Due to the observation of residual myeloma cells in the graft; several years ago, attempts were made to purify the grafts with CD34+ selection [3, 4] . Due to technical difficulties, these efforts were unsuccessful and resulted in worsened recovery of blood cell counts post-high dose melphalan (HDM) resulting in increased risk of severe post-transplant infections [4] .
We were motivated to perform a prospective study using modern carfilzomib/lenalidomide/dexamethasone (KRd) combination therapy to assess minimal residual disease (MRD) status both in patients and their corresponding HPC grafts. Also, we were interested in evaluating the yield of HPC in relation to the number of given cycles of KRd combination therapy prior to collection of stem cells for ASCT (per protocol: up to 8 cycles) [5] .
For HPC mobilization, all patients received 5 days of filgrastim at 10-16 mcg/kg/dose, with circulating CD34 count assessed 12 h after the 4th dose (see Table 1 ). Prior mobilization data derived from healthy HPC apheresis donors was used to generate a regression formula, y = 0.45x + 0.86, where x = the pre-apheresis circulating CD34 count after the 5th dose of filgrastim, and y = the expected yield of the apheresis procedure, expressed as millions of CD34 cells harvested per liter processed [6] . Per institutional guidelines at the National Institutes of Health (NIH), the targeted yield was ≥4 × 10 6 CD34 cells/kg, with minimum acceptable yield ≥2 × 10 6 CD34 cells/kg. Plerixafor 240 mcg/kg was given with the 5 th dose of filgrastim, 8-10 h prior to apheresis, if the regression equation predicted a CD34 cell yield of <4 × 10 6 CD34 cells/kg in a single procedure with a maximum of 30 liters processed. The actual volume processed was based on the stat blood CD34 count drawn immediately prior to apheresis. Procedures were performed on the Cobe Spectra device (https://www.terumobct.com/cobe-spectra); continuous intravenous calcium was used to mitigate citrate toxicity.
Product contamination with residual myeloma cells (i.e., MRD status of the HPC graft) was evaluated in stored frozen HPC grafts using multi-parameter flow cytometry (Table 2 ) [5] [6] [7] . Per current International Myeloma Working Group (IMWG) criteria [6] assessments of MRD status of the bone marrow aspirates (i.e., MRD status of the patient) was performed at the time the patient reached a response of complete response (CR) in serum/urine, or at the completion of 8 cycles of KRd combination therapy, whichever occurred earlier.
In this study, we included 30 previously untreated patients enrolled on clinical trials designed to give KRd combination therapy prior to collection of stem cells for ASCT; the clinical trials gave a total of 8 cycles of KRd and per protocol stem cell collection was permitted after 4 (up to For stem cell mobilization, subcutaneous injections of G-CSF were administered for 5 consecutive days at a daily dose of 10-16 µg/kg. The need for an additional mobilizing agent (plerixafor) to be given on day 4 of mobilization was evaluated in real time in each patient, based on the peripheral blood CD34 count on the morning of day 4 of G-CSF administration. Patients with a peripheral CD34+ cells count of greater than or equal to 42 cells/μl performed on the morning of day 4, a minimum of 3 h after the 4th G-CSF administration did not receive plerixafor but received a 5th dose of G-CSF in the morning of day 5.
Patients with a peripheral CD34+ cells count of <42 cells/μl on the morning of day 4 of G-CSF administration received either filgrastim alone on day 5 of mobilization or both plerixafor in evening of day 4 and filgrastim in the morning of day 5 of mobilization, depending on their weight and their circulating CD34 count, as described in Table 1 . Apheresis was performed day 5 of mobilization, a minimum of 3 h after the administration of the 5th G-CSF dose (and plerixafor, if indicated). The collection target dose was 5 × 10 6 CD34+ cells/kg, to be sufficient for a double AHCT if clinically indicated (Minimum dose: 4 × 10 6 CD34+ cells/kg for a double transplant and 2 × 10 6 CD34+ cells/kg for a single-autologous transplant) The mean CD34 cell count in the entire group after the 4th dose of filgrastim was 29/μL (range 2-88/μL). Using the regression formula as a guide, 17/30 (57%) of patients received plerixafor. The CD34 counts increased 4.2-fold in patients receiving plerixafor, from 15 ± 9/μL (m ± SD) on the day prior to apheresis to 53 ± 30/μL immediately preapheresis; CD34 counts did not change in patients who received filgrastim alone (from 48 ± 17/μL to 45 ± 19/μL). Guided by the stat pre-apheresis CD34 count, the volume processed in the first apheresis procedure was the same, 23 ± 7 (range 12-30) liters, with or without plerixafor. CD34 cells were collected with 72 ± 14% efficiency. As shown in Fig. 1 , the yield of the stem cell collection was very similar for patients who had collections after 4, 5, 6, and 7 cycles of KRd, respectively.
At the time of HPC collection, 16 (53.3%) patients were in CR/stringent-(s)-CR/near-(n)-CR (11 CR/sCR and 5 nCR), 10 (33.3 %) had very good partial response (VGPR) with 3 partial response (PR) (10%) and 1 stable disease (SD) (3.3%). Patients received a median of 5 prior KRd cycles with a median of 12 days (range 1-34) between mobilization and last lenalidomide dose as part of the KRd combination therapy. At the time of HPC collection, 11 of 30 patients (36.6%) were MRD negative per IMWG criteria [6] . All of these 11 patients who were MRD negative also had HPC grafts which were MRD negative (Fig. 1,  panel B) . Interestingly, 18 of the 19 patients who were MRD positive in their bone marrows were MRD negative in their HPC grafts. Thus, only one of the MRD positive patients was MRD positive in the HPC graft. This single patient was a 66 year old Caucasian male with IgG Kappa multiple myeloma who had his HPC graft collected after 6 cycles of KRd and was in PR at the time.
Although only 30 patients were included in this study, given that all patients were treated with the same KRd therapy on prospective clinical trials and all MRD assessments were conducted in a uniform manner at a single Fig. 1 a Stem cell collection yield in relation to number of given cycles of KRd combination therapy. The mean CD34 cell count in the entire group after the 4th dose of filgrastim was 29/μL (range 2-88/ μL). Using the regression formula as a guide, 17/30 (57%) of patients received plerixafor. The CD34 counts increased 4.2-fold in patients receiving plerixafor, from 15 ± 9/μL (m ± SD) on the day prior to apheresis to 53 ± 30/μL immediately pre-apheresis; CD34 counts did not change in patients who received filgrastim alone (from 48 ± 17/μL to 45 ± 19/μL). Guided by the stat pre-apheresis CD34 count, the volume processed in the first apheresis procedure was the same, 23 ± 7 (range 12-30) liters, with or without plerixafor. CD34 cells were collected with 72 ± 14% efficiency. First-procedure CD34 cell yields were 6.4 ± 2.5 × 10 6 /kg (range 2.5-10.1) with supplemental plerixafor vs 5.8 ± 2.5 × 10 6 /kg (range 1.1-9.3) with filgrastim alone. Only two of 30 patients underwent a second procedure; neither received plerixafor prior to the first procedure, and both received it prior to the second. In one patient, criteria for plerixafor administration were met, but the drug was inadvertently not given prior to the first procedure; in the second patient, an unexpectedly low pre-apheresis CD34 count was traced to inadequate self-administration of the 5th dose of filgrastim. All 30 patients achieved the minimum CD34 collection goal of ≥2 × 10 6 cells/kg and 29/30 reached this with one procedure. The higher targeted collection goal of ≥4 × 10 6 CD34 cells/kg was achieved in a single procedure by 86% (24/28) of patients in both the plerixafor group and the filgrastim-alone group. The median stem cell yield of 13 patients who were collected at cycle 4 was 7.4 million/kg (range 3.5-11) as compared with 6.1 million/kg (range 2.4-10) in 17 patients who were collected after cycles 1-7. b Minimal residual disease (MRD) status in individual patient's bone marrow, as well as collected HPC grafts. Red = MRD positive. Green = MRD negative laboratory, these findings are of important clinical value. The results illustrate the fact that the amount of circulating myeloma cells in peripheral blood is substantially lower than that observed in bone marrow aspirates; this is particularly true after 4 or more cycles of KRd combination therapy. The HPC grafts collected for ASCT were consistently negative with the exception for one of 30 (3.3%) patients. Also, this study shows that, compared to older regimens, KRd combination therapy does not impair HPC mobilization response to filgrastim in patients with myeloma. Indeed, we show similar HPC yield after 4, 5, 6, and 7 cycles of KRd (Fig. 1a) .
Our results show that induction treatment with KRd does not appear to impair HPC mobilization response to filgrastim in patients with plasma cell dyscrasias compared to older regimens [8, 9] . Traditionally, adding high-dose cyclophosphamide to G-CSF has been used to increase HPC yields. Our results in conjunction with recently published studies show that in the era of novel agents, mobilization of HPCs by growth factors alone is an effective alternative to the chemotherapy mobilization [10] . In this study, we employed a previously published algorithm that uses the CD34 cell count after 4 doses of filgrastim to predict the following day's pre-apheresis CD34 count and thus determine whether plerixafor supplementation is needed. Expectedly, the use of plerixafor caused a multi-fold increase in CD34 counts. The algorithm allowed 13 of 30 (43%) patients to avoid the use of plerixafor.
In 2018, many centers still give 4 cycles of combination therapy as their default number of induction cycles. This comes from the older VAD regiment which was cardiotoxic and limited the number of cycles to a maximum of 4 [3, 4] . With the KRd regiment, such restrictions do not apply [5] . Importantly, we previously reported that newly diagnosed multiple myeloma patients treated with KRd on average took 6 cycles of therapy until they reached MRD negativity in their bone marrow [5] . This observation in combination with the current study showing that the HPC collection yield was similar after >4 (up to 8 allowed) cycles of KRd suggesting that 6 cycles of KRd is an efficacious and safe induction strategy for patients who are planning to collect stem cells. At the present time, at Memorial Sloan Kettering Cancer Center (MSKCC), we consider 6 cycles of KRd combination therapy to be an optimal induction therapy for fit untreated multiple myeloma patients and we have implemented that as the standard of care prior to collection of stem cells for HDM-ASCT [11] . Currently, we are developing daratumumab-KRd combination therapy as part of an ongoing phase 2 clinical trial https://clinicaltrials.gov/ ct2/results?cond=NCT03290950&term=&cntry=&state= &city=&dist=, and, when completed, we will compare the efficacy and safety with our KRd experience.
